Peak Cloud 456 +8

After an initial buying mood, the market is in a deadlock. After the end of trading on the 20th, it announced an upward revision of the financial estimates for the August 2024 period. It has revised its operating profit upward by 35% from its previous estimate of 200 million yen to 270 million yen (163 million yen in the previous period). This is due to factors such as orders for digital signage-related businesses in the third quarter exceeding expectations, revenue and operating profits progressing beyond the planned levels, and the fact that the amount of goodwill amortization resulting from the integration with Cloudpoint was lower than originally anticipated, pushing up operating profit.

WASH House 361 +20

Rapid surge. After the close of trading on the 20th, it was announced that a presentation for the company's self-developed original washing machine and dryer will be held on July 20th. The company has been developing original washing machines and dryers necessary to achieve its goal of providing "free laundry" since its founding. Introducing this new machinery into the market will not only affect future business development, but also change the industry norm significantly.

Circu 725 +18

Rising. After the close of trading on the 20th, announced the acquisition of its own shares in the Tokyo Stock Exchange's off-auction own share purchase (TOSTNET-3) on the morning of the 21st, up to a maximum of 480,000 shares. This was in response to the intention of former Executive Director Masatoshi Kubota's asset management company to dispose of 434,000 shares of held shares, and as planned on the 21st, the buying was implemented, with a all filled quantity of 434,000 shares, the same number as the shares that Kubota's asset management company had indicated an intention to dispose of.

Immune Biology Research Institute 519 +4

Still on the rise. AI Bio, a subsidiary of the company, has announced that it has signed an exclusive licensing agreement with SML Biopharm in South Korea to use the antibody gene sequence for severe fever thrombocytopenia syndrome (SFTS) virus as a therapeutic purpose. AI Bio had been exploring early derivation of therapeutic neutralizing antibodies for SFTS virus, which is a tick-borne infectious disease. Although the impact on the financial results for the fiscal year ending in March 2025 is minimal due to the relatively small initial fee made in the licensing agreement, it is expected to contribute to the improvement of the company's mid- to long-term earnings and its corporate value, and this has led to buying interest.

Image Information Co., Ltd. 440 +8

Rebounding. The stock is being bought after it announced an upward revision of its earnings forecast for the fiscal year ending in March 2025 in the after-hours trading on the 20th. The company significantly revised the final profit and loss for the fiscal year ending in March 2025 from its previous projection of 7 million yen to 75 million yen in profit (compared to a loss of 20 million yen in the previous year). The company said it revised the forecast based on the occurrence of special profits and losses after announcing its earnings forecast on May 15, 2024, as well as a review of the earnings forecast. The company did not disclose its earnings forecast for the first half (April-September 2024).

JDSC 704 -59

Significant decline. The company announced a revision of its earnings forecast for the fiscal year ending June 2024 after the market closed on the 20th. The company sharply lowered operating profit from its previous forecast of 120 million yen to 30 million yen (compared to 68 million yen in the previous year), reversing its outlook for an increase. As a result of strategic alliances such as SCSK's capital business partnership that are expected to contribute to future profit growth and investing in excellent personnel who support profit growth after June 2025 for AI solution business, personnel costs have increased and operating profit fell below expectations.